|

CD19/CD22-CAR T cells Clinical Trials

2 actively recruiting trials

Also known as: EB-BH2024

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

  • University College, London1
  • Essen Biotech1

Indications

  • Cancer2
  • MCL1
  • Lymphoma, Follicular1
  • Acute Lymphoblastic Leukemia, Adult B-Cell1
  • Central Nervous System Lymphoma1

Other2 trials

CARPALL: Immunotherapy with CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia
Phase 1
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.